Nasdaq Market Makers Antitrust Litigation

Lowey Dannenberg, P.C. Congratulates Seven of its Attorneys Named to New York Metro Super Lawyers® and Rising Stars 2023

Retrieved on: 
Friday, September 22, 2023
2018 AFL Women's Rising Star, Nasdaq Market Makers Antitrust Litigation, Rising Star, Securities Litigation Uniform Standards Act, Research, Lawyer, Thomson Reuters, Class, Tobacco

is proud to announce that three of its attorneys have been included in this year’s Super Lawyers® list for their exceptional work in complex litigation: Vincent Briganti (Antitrust Litigation), Peter St. Phillip (Antitrust Litigation), and Peter Barile (Antitrust Litigation).

Key Points: 
  • is proud to announce that three of its attorneys have been included in this year’s Super Lawyers® list for their exceptional work in complex litigation: Vincent Briganti (Antitrust Litigation), Peter St. Phillip (Antitrust Litigation), and Peter Barile (Antitrust Litigation).
  • Additionally, four of its attorneys have been named 2023 Rising Stars by Super Lawyers®: Christian Levis (Class Action), Andrea Farah (Securities Litigation), Nicole Veno (Antitrust Litigation), and Amanda Fiorilla (Class Action).
  • These honors recognize the outstanding contributions that our attorneys have made in the fields of class actions, securities litigation, and antitrust litigation, and peer recognition of their achievements.
  • Only 5% of all practicing attorneys in each state are selected to the annual Super Lawyers® lists, and even fewer, 2.5%, are chosen as Rising Stars.

Norwood Financial Corp Holds Annual Meeting Of Shareholders

Retrieved on: 
Friday, April 28, 2023
Nasdaq Market Makers Antitrust Litigation, Annual Meetings of the International Monetary Fund and the World Bank Group, P.C, Annual general meeting, Management, Security (finance)

HONESDALE, Pa., April 28, 2023 (GLOBE NEWSWIRE) -- The 152nd Annual Meeting of Shareholders of Norwood Financial Corp (Nasdaq-NWFL), parent company of Wayne Bank, was held on Tuesday, April 25, 2023, in a virtual meeting format.

Key Points: 
  • HONESDALE, Pa., April 28, 2023 (GLOBE NEWSWIRE) -- The 152nd Annual Meeting of Shareholders of Norwood Financial Corp (Nasdaq-NWFL), parent company of Wayne Bank, was held on Tuesday, April 25, 2023, in a virtual meeting format.
  • The Annual Meeting also included presentations to shareholders from President and Chief Executive Officer, James O. Donnelly and Executive Vice President and Chief Financial Officer, William S. Lance.
  • He then turned the meeting over to Mr. Donnelly, who conducted the formal business portion of the meeting.
  • Norwood Financial Corp, through its subsidiary Wayne Bank, operates fourteen offices in Northeastern Pennsylvania and fifteen offices in Delaware, Sullivan, Ontario, Otsego and Yates Counties, New York.

VEON confirms revised timing for effectiveness of ratio change under its American Depositary Receipt (“ADR”) program

Retrieved on: 
Tuesday, March 7, 2023
Euronext Amsterdam, Ratio, CUSIP, DTCC, ADR, ADS, VEON, Depository Trust & Clearing Corporation, Effective date, ADR Institute of Alberta, Nasdaq Market Makers Antitrust Litigation, BNY Mellon, Security (finance)

DTCC has now confirmed the availability of the new CUSIP, and the effective date of the Ratio Change (the “Effective Date”) is now confirmed as 8 March 2023.

Key Points: 
  • DTCC has now confirmed the availability of the new CUSIP, and the effective date of the Ratio Change (the “Effective Date”) is now confirmed as 8 March 2023.
  • American Depositary Share (“ADS”) beneficial holders who hold through an ADR holder intermediary need not take any action in connection with the Ratio Change.
  • For ADS holders, the Ratio Change will have the same effect as a one for twenty five reverse ADS split.
  • The Company’s original announcement with respect to the ratio change can be found on the Company’s website at this address:

Eight Keller/Anderle Lawyers named to Super Lawyers - SoCal

Retrieved on: 
Wednesday, February 1, 2023
Justice, Corporate law, Law of the United Kingdom, Thomson Reuters, Nasdaq Market Makers Antitrust Litigation, Professional liability insurance, Security (finance), Supreme court, Competition law, Winston-Salem Entertainment-Sports Complex, Aviation, U.S. Department of Defense Strategy for Operating in Cyberspace, Jennifer Keller, Intellectual property, Health insurance coverage in the United States, White collar, Property management

Jennifer Keller has been ranked either #1 or #2 attorney in Southern California by Super Lawyers for five consecutive years, from 2019 to 2023.

Key Points: 
  • Jennifer Keller has been ranked either #1 or #2 attorney in Southern California by Super Lawyers for five consecutive years, from 2019 to 2023.
  • Kay Anderle , managing partner, has been named to Business Litigation and White Collar Criminal Defense.
  • Chase Scolnick , partner, named to Civil Litigation-Defense and White Collar Criminal Defense, specializes in complex civil and criminal litigation.
  • Anand Sambhwani , named for Business Litigation, Civil Litigation, Intellectual Property Litigation, and Securities Litigation, has a Commercial Litigation background with the U.S. Department of Justice in Washington, D.C.

Motos America Provides Year-End 2022 Shareholder Update

Retrieved on: 
Tuesday, February 7, 2023
Marketing, Nasdaq Market Makers Antitrust Litigation, Triumph, New Year, Metric, Acquisition, Motorcycle, SALT, Davis Technical College, Common, ROI, OTC, BMW Motorrad, Trustee, Letter, The, Special Project, Senate, Senior, Growth, HACCP, BMW, Deseret Digital Media, Car dealership, Financial services, Management, Daytona, Husqvarna

SALT LAKE CITY, UT, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Motos America Inc. (OTC PINK: MTAM) (the “Company”) a luxury European motorcycle dealership consolidation company and lifestyle brand, provides today a year-end 2022 shareholder update from CEO Vance Harrison.

Key Points: 
  • SALT LAKE CITY, UT, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Motos America Inc. (OTC PINK: MTAM) (the “Company”) a luxury European motorcycle dealership consolidation company and lifestyle brand, provides today a year-end 2022 shareholder update from CEO Vance Harrison.
  • With 8 dealerships now acquired, Motos America is emerging as a trusted name in the luxury European motorcycle market.
  • We will continue to execute our disruptive consolidation model throughout the coming years, a significant milestone in our pursuit of building long-term shareholder value,” stated Motos America CEO, Vance Harrison.
  • The selection of Motos America for this open-point dealership was confirmed following a meeting in BMW’s home market of Germany between Motos America CEO Vance Harrison and President Kris Odwarka with top BMW executives.

VEON announces ratio change under its American Depositary Receipt (“ADR”) program

Retrieved on: 
Monday, February 6, 2023
Euronext Amsterdam, Ratio, Nasdaq Market Makers Antitrust Litigation, ADR, ADSS, ADS, Effective date, American depositary receipt, VEON

The effective date of the Ratio Change (the “Effective Date”) is expected to be 6 March 2023.

Key Points: 
  • The effective date of the Ratio Change (the “Effective Date”) is expected to be 6 March 2023.
  • ADS beneficial holders who hold through an ADR holder intermediary need not take any action in connection with the Ratio Change.
  • For ADS holders, the Ratio Change will have the same effect as a one for twenty five reverse ADS split.
  • While the Ratio Change is intended to bring the bid price of the Company’s ADSs into compliance with the Minimum Bid Price, the Company can give no assurance that the Ratio Change will be effective in achieving this goal.

Hagens Berman Promotes Six Attorneys – Including Five Women – to Partner in 2023

Retrieved on: 
Wednesday, January 4, 2023
Women, Consumer, Professional Services, Legal, DEI (Diversity, Equity and Inclusion), Ignition, Oxford-Whitney Streets Historic District, United States Court of Appeals for the Third Circuit, Veni, vidi, vici, Ezetimibe, HIV, Bosentan, Broiler, Employment, Nasdaq Market Makers Antitrust Litigation, Privacy, Human, Celecoxib, Eye, Adalimumab, Patent, Insulin, Woman, Pharmaceutical industry

Hagens Berman, a global plaintiffs’ class-action law firm, promoted six attorneys – five of whom are women – to partner in 2023, the firm’s 30th year of fighting for the rights of those who need it most.

Key Points: 
  • Hagens Berman, a global plaintiffs’ class-action law firm, promoted six attorneys – five of whom are women – to partner in 2023, the firm’s 30th year of fighting for the rights of those who need it most.
  • “We know that what makes any team strong is its players, and we’re delighted to continue to strengthen our roster of extraordinary partners,” Berman said.
  • The six attorneys come from across four of the firm’s offices, representing exceptional lawyering across a variety of practice areas.
  • Hannah Brennan focuses on drug pricing, consumer access to medications, healthcare fraud, antitrust and patent fraud at the firm’s Boston office.

Mitesco, Inc. Sets Stock Split Date, Readies for Uplist, Increases Shareholders Equity

Retrieved on: 
Friday, December 9, 2022
Diamond, Acquisition, Good clinical laboratory practice, Financial Industry Regulatory Authority, Practitioner, Nasdaq Market Makers Antitrust Litigation, Book, FINRA, Good, Exercise, MinuteClinic, OTCQB, MITI, Form, Security (finance)

The reverse split is in a ratio of 50:1, and any fractional shares as a result of the split will be rounded up to a single share.

Key Points: 
  • The reverse split is in a ratio of 50:1, and any fractional shares as a result of the split will be rounded up to a single share.
  • Immediately after the reverse stock split becomes effective, the Company will have approximately 4.5 million shares of common stock outstanding.
  • Further, we are resetting our balance sheet and shareholder’s equity such that we will meet those requirements as well,” explained Larry Diamond, CEO.
  • Following the effectiveness of the reverse stock split, each stock certificate and book-entry or other electronic position representing issued and outstanding shares of the Company's common stock will be automatically adjusted.

Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem™, a Novel Cell Therapy for the Treatment of Type 1 Diabetes

Retrieved on: 
Thursday, November 3, 2022
NASDAQ, Injury, Security (finance), Urology, IND, Elective surgery, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Toxicity, Clinical trial, FDA, Diabetic ketoacidosis, Program, Seizure, Hypoglycemia, Forward-looking statement, News, Pacific Northwest Diabetes Research Institute, Nasdaq Market Makers Antitrust Litigation, Nerve Damage, Stroke, CEO, Research, Food, Therapy, Eye disease, View, PRDC, Type 1 diabetes, U.S. Securities and Exchange Commission, Nutrient, Pancreas, Consciousness, Patient, Death, Company, Translation, Investigational New Drug, Diabetes, Immunotherapy, T1D, University, Microbiology, Type 1, Coma, Degenerative disease, Biomedical engineering, Endocrinology, Insulin, Neurology, Multimedia, Severe cognitive impairment, Commission, Immunology, Ageing, Pharmaceutical industry, Medical device

PHOENIX, Nov. 3, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), an immuno-endocrine company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug (IND) application, enabling the Company to proceed with initiating a clinical trial for Type 1 Diabetes using AlloStem™.

Key Points: 
  • The primary objective of the study (CELZ-201) is to evaluate AlloStemin patients with newly diagnosed Type 1 Diabetes.
  • "This is a milestone event for Creative Medical Technology Holdings as it marks the Company's first IND clearance from the FDA," said Timothy Warbington, CEO.
  • See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov .
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/creative-medical-technology-hol...
    SOURCE Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings Develops AlloStem™ Clinical Cell Line

Retrieved on: 
Thursday, October 20, 2022
News, Primary ovarian insufficiency, Nasdaq Market Makers Antitrust Litigation, Time, Cell bank, U.S. Securities and Exchange Commission, Immortalised cell line, Investigational New Drug, Drug, Drug Master File, Commission, NASDAQ, Biotechnology, Security (finance), Multimedia, Urology, Neurology, CEO, Endocrinology, Immunotherapy, Forward-looking statement, Low back pain, Elective surgery, FDA, View, Pharmaceutical industry, 3D printing

PHOENIX, Oct. 20, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, neurology, and orthopedics, announced today that through predominantly internal and collaborative development, it has produced an allogenic Cell Line called AlloStem, which includes a Master Cell Bank and a Drug Master File which shall be submitted for FDA registration.

Key Points: 
  • PHOENIX, Oct. 20, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, neurology, and orthopedics, announced today that through predominantly internal and collaborative development, it has produced an allogenic Cell Line called AlloStem, which includes a Master Cell Bank and a Drug Master File which shall be submitted for FDA registration.
  • Creative Medical Technology Holdings, Inc. is a biotechnology company specializing in regenerative medicine/stem cell technology in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics and is traded on NASDAQ under the ticker symbol CELZ.
  • See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov .
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/creative-medical-technology-hol...
    SOURCE Creative Medical Technology Holdings, Inc.